4D Molecular Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(160,868) | $(100,837) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 26,116 | 19,665 |
| Vesting of common stock warrants in return for services | 66 | 88 |
| Change in fair value of derivative liability | 41 | 157 |
| Depreciation and amortization | 4,653 | 4,204 |
| Amortization of right-of-use assets | 2,052 | 1,545 |
| Net amortization (accretion) of premium (discount) on marketable securities | (7,182) | (1,244) |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | (1,699) | (1,399) |
| Other assets | (3,577) | (70) |
| Accounts payable | 871 | 896 |
| Accrued and other liabilities | 6,524 | 3,371 |
| Deferred revenue | 69 | (715) |
| Operating lease liabilities | (1,651) | (1,453) |
| Net cash used in operating activities | (134,585) | (75,792) |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (3,786) | (2,771) |
| Purchase of marketable securities | (467,652) | (54,802) |
| Maturities of marketable securities | 169,001 | 173,290 |
| Net cash provided by (used in) investing activities | (302,437) | 115,717 |
| Cash flows from financing activities | ||
| Issuance of common stock upon public offerings, net of issuance costs | 316,149 | 129,208 |
| Issuance of common stock upon exercise of stock options and warrants | 4,580 | 7,310 |
| Issuance of common stock - 2020 ESPP | 1,258 | 1,178 |
| Issuance of common stock for the ATM offering program, net of issuance costs | 15,263 | 19,136 |
| Net cash provided by financing activities | 337,250 | 156,832 |
| Net increase (decrease) in cash and cash equivalents | (99,772) | 196,757 |
| Cash and cash equivalents, beginning of period | 249,108 | 52,351 |
| Cash and cash equivalents, end of period | $149,336 | $249,108 |
| Supplemental disclosures of noncash investing and financing information | ||
| Purchases of property and equipment in accounts payable and accrued and other liabilities | $509 | $234 |
| Right-of-use assets obtained in exchange for lease obligations | $11,587 | $— |
| Deferred ATM costs reclassification | $— | $468 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.